Abstract
The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 517-524 |
| Number of pages | 8 |
| Journal | Dermatologic clinics |
| Volume | 30 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 1 2012 |
Fingerprint
Keywords
- Immunotherapy
- Metastatic melanoma
- Signaling pathways
- Targeted therapies
ASJC Scopus subject areas
- Dermatology
Cite this
}
Targeted Therapies for Metastatic Melanoma. / Chandra, Sunandana; Pavlick, Anna C.
In: Dermatologic clinics, Vol. 30, No. 3, 01.07.2012, p. 517-524.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Targeted Therapies for Metastatic Melanoma
AU - Chandra, Sunandana
AU - Pavlick, Anna C.
PY - 2012/7/1
Y1 - 2012/7/1
N2 - The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
AB - The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
KW - Immunotherapy
KW - Metastatic melanoma
KW - Signaling pathways
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=84863865785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863865785&partnerID=8YFLogxK
U2 - 10.1016/j.det.2012.05.001
DO - 10.1016/j.det.2012.05.001
M3 - Review article
VL - 30
SP - 517
EP - 524
JO - Dermatologic Clinics
JF - Dermatologic Clinics
SN - 0733-8635
IS - 3
ER -